phrykt

Harmony Biosciences Holdings, Inc. (HRMY): who owns it and who trades it

As of Nov 16, 2026, HRMY insiders reported 13 open-market sales worth $6M and no purchases in the last 12 months, with 48% of the sale value made under pre-set 10b5-1 plans. The largest seller was Kumar Budur (CHIEF MEDICAL OFFICER), with $3.1M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Harmony Biosciences Holdings

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns HRMY

327 funds and institutions reported HRMY shares worth $2B at the end of Q2 2026, about 98% of the company. The largest holder is BlackRock, Inc. with 12.3%.

Funds and institutions (13F) 98%Everyone else 2%

10 largest owners, by share of the company

BlackRock, Inc.12.3%
FMR LLC (Fidelity)6.2%
Vanguard Portfolio Management LLC5.0%
American Century Companies Inc4.4%
Dimensional Fund Advisors LP4.1%
Vanguard Capital Management LLC3.6%
Lsv Asset Management3.6%
California State Teachers Retirement System3.6%
State Street Corp3.2%
Armistice Capital, LLC2.7%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.7.10M12.27%$259M+0%
FMR LLC (Fidelity)3.57M6.17%$130M+13%
Vanguard Portfolio Management LLC2.88M4.98%$105M+6%
American Century Companies Inc2.54M4.39%$92.5M+21%
Dimensional Fund Advisors LP2.39M4.13%$87.1M+15%
Vanguard Capital Management LLC2.11M3.64%$76.6M+0%
Lsv Asset Management2.06M3.56%$75M+2%
California State Teachers Retirement System2.06M3.56%$56.6M–
State Street Corp1.86M3.21%$67.7M+4%
Armistice Capital, LLC1.56M2.70%$56.9M-4%
Geode Capital Management, LLC1.44M2.49%$52.5M+9%
Arrowstreet Capital, Limited Partnership1.31M2.27%$47.8M-5%
Renaissance Technologies LLC1.20M2.06%$43.5M+11%
Two Sigma Investments, LP959,1361.66%$34.9M+31%
AQR Capital Management LLC934,3261.61%$34M+30%
SG Americas Securities, LLC882,7201.52%$32.1M-56%
Valor Management LLC818,0131.41%$29.8M+598%
Morgan Stanley733,6841.27%$26.7M-29%
UBS Group AG602,9901.04%$22M+35%
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main551,0750.95%$20.1M-3%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, HRMY insiders reported $0 of open-market purchases and $6M of sales. 48% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$6M
13 trades, 3 people
Sales under a 10b5-1 plan
48%
Share of sale value
Latest trade
Sep 18, 2026
Filed Sep 18, 2026

Purchases and sales by month

$3.1M$3.1MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 18, 2026Kumar BudurCHIEF MEDICAL OFFICERSale35,852$43.05$1.5MForm 4
Sep 17, 2026Kumar BudurCHIEF MEDICAL OFFICERSale800$43.00$34.4KForm 4
Sep 16, 2026Kumar BudurCHIEF MEDICAL OFFICERSale1,800$43.01$77.4KForm 4
Sep 8, 2026Kumar BudurCHIEF MEDICAL OFFICERSale22,954$43.10$989KForm 4
Sep 8, 2026Kumar BudurCHIEF MEDICAL OFFICERSale1,000$42.79$42.8KForm 4
Sep 8, 2026Kumar BudurCHIEF MEDICAL OFFICERSale4,500$42.25$190KForm 4
Sep 4, 2026Kumar BudurCHIEF MEDICAL OFFICERSale5,500$41.98$231KForm 4
Jan 26, 2026Sandip KapadiaCFOSale plan3,746$37.15$139KForm 4
Jan 15, 2026Sandip KapadiaCFOSale plan20,961$35.92$753KForm 4
Dec 12, 2025Jeffrey M. DaynoCEOSale plan5,933$40.11$238KForm 4
Dec 12, 2025Jeffrey M. DaynoCEOSale plan20,000$40.11$802KForm 4
Dec 5, 2025Sandip KapadiaCFOSale plan20,000$39.54$791KForm 4
Nov 21, 2025Sandip KapadiaCFOSale plan3,427$35.00$120KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Kumar BudurCHIEF MEDICAL OFFICER–$3.1MSep 18, 2026
Sandip KapadiaCHIEF FINANCIAL OFFICER–$1.8MJan 26, 2026
Jeffrey M. DaynoPRESIDENT, CEO, Director–$1MDec 12, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

HRMY short interest

High short interest. 11.4% of HRMY shares are sold short: about 1 share in 9. Over the last 12 reports the number of shares short went up 1%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 6.66M HRMY shares were sold short, 11.4% of the shares outstanding, up 23.1% from the report before. At the average daily volume of 1.18M shares, buying them all back would take about 5.6 trading days (days to cover).

Shares short, % of all shares

11.4%May 15Oct 3012.1%

Days to cover

5.6May 15Oct 309.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20266.66M11.44%+23%1.18M5.6
Oct 15, 20265.41M9.30%-2%876,1056.2
Sep 30, 20265.53M9.50%+20%1.11M5.0
Sep 15, 20264.63M7.95%-10%1.07M4.3
Aug 31, 20265.16M8.87%+25%566,6509.1
Aug 14, 20264.14M7.10%-8%866,8054.8
Jul 31, 20264.50M7.72%-12%889,7015.0
Jul 15, 20265.11M8.84%+11%754,0936.8
Jun 30, 20264.61M7.97%-1%809,5665.7
Jun 15, 20264.65M8.02%-22%894,7515.2
May 29, 20265.94M10.26%-10%689,1108.6
May 15, 20266.62M11.43%-4%805,9118.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Harmony Biosciences Holdings company events

Harmony Biosciences Holdings filed 11 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership). The latest was on Nov 4, 2026.

  1. Nov 4, 2026ResultsReleased financial results. Filing
  2. Oct 30, 2026LeadershipAmended an earlier report. Of the Current Report on Form 8-K filed by Harmony Biosciences Holdings, Inc. on October 13, 2026. Filing
  3. Oct 13, 2026LeadershipHarmony Biosciences Holdings, Inc. announced that Jeffrey M. Dayno, M.D., as part of a leadership succession plan, will be retiring as the Company’s President and Chief Executive Officer and stepping down as a Class I director of the Company’s Board of Directors, in each case, effective as of… Filing
  4. Aug 4, 2026ResultsReleased financial results. Filing
  5. Jul 16, 2026LeadershipThe Company announced that Glenn Reicin, the Company’s Chief Financial Officer, will be stepping down as the Company’s Chief Financial Officer effective as of July 16, 2026 to pursue other career opportunities. ​ In connection with his departure from the Company, on July 16, 2026, the Company and… Filing
  6. May 14, 2026VoteReported shareholder vote results. Filing
  7. May 7, 2026ResultsReleased financial results. Filing
  8. Apr 14, 2026LeadershipHarmony Biosciences Holdings, Inc. announced that Sandip Kapadia, the Company’s Chief Financial Officer, will be stepping down as the Company’s Chief Financial Officer effective as of April 14, 2026 to pursue other career opportunities. Filing
  9. Apr 2, 2026LeadershipHarmony Biosciences Holdings, Inc. named Peter Anastasiou the Company’s Senior Executive Vice President and Chief Operating Officer, effective April 2, 2026. Filing
  10. Feb 24, 2026ResultsReleased financial results. Filing
  11. Jan 12, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Harmony Biosciences Holdings financials

Famous investors that hold HRMY

4 of the 50 well-known investors we track reported holding HRMY in their latest 13F filing. The largest position is Jim Simons's, worth $54.9M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 20261.40M$54.9M0.1%+17%
Ray Dalio · Bridgewater AssociatesQ3 2026270,269$10.6M0.0%+9%
Israel Englander · Millennium ManagementQ3 202620,952$823K0.0%-93%
Jeremy Grantham · GMOQ3 202612,970$509K0.0%+19%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named HRMY in the last 120 days.

FiledHolderFormStake
Oct 27, 2026BlackRock, Inc.13G/A12.6%
Oct 27, 2026BlackRock, Inc.13G/A12.6%

Questions about Harmony Biosciences Holdings, Inc. (HRMY) stock

Who owns the most HRMY stock?

The largest reported owner of Harmony Biosciences Holdings, Inc. (HRMY) is BlackRock, Inc., with 12.3% of the company. In total, 327 funds and institutions reported holding HRMY at the end of Q2 2026, together about 98% of the shares. See the largest owners.

Are HRMY insiders buying or selling?

In the last 12 months, HRMY insiders reported no open-market purchases and 13 sales worth $6M. The latest trade was on Sep 18, 2026. See every trade.

What is the short interest in HRMY?

As of Oct 30, 2026, 6.66M HRMY shares were sold short, 11.4% of the shares outstanding, up 23.1% from the report before. At the average daily volume of 1.18M shares, buying them all back would take about 5.6 trading days (days to cover). See the history.

Which famous investors hold HRMY?

4 of the 50 well-known investors we track reported HRMY in their latest 13F filing, including Jim Simons, Ray Dalio, Israel Englander. The largest position is worth $54.9M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.